• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重症肌无力患者的就业状况:系统文献回顾和荟萃分析。

Employment in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis.

机构信息

UOC Neurologia, Salute Pubblica, Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy,

Dipartimento di Ricerca e Sviluppo Clinico, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.

出版信息

Neuroepidemiology. 2020;54(4):304-312. doi: 10.1159/000506310. Epub 2020 Feb 25.

DOI:10.1159/000506310
PMID:32097937
Abstract

INTRODUCTION

Myasthenia gravis (MG) is an autoimmune disease whose period of typical onset is around 20-40 years (i.e., early onset), thus in the peak of working age, or around 60-80 years (i.e., late onset). However, the information on work-related issues and employment status are sparse and not systematically reported. Therefore, we performed a systematic literature review with meta-analysis to address the employment status of MG patients.

METHODS

We searched for papers reporting employment status on participants with MG published between January 2000 and May 2019. Information on employment was extracted. Random-effects models were used to produce meta-analytic estimates for the proportion of employed patients.

RESULTS

In total, 1,045 records were retrieved, of which 19 fitted the inclusion criteria. In total, 3,600 participants (average age 47.5, range 35-60) were included in the studies and 1,579 of them were employed. The proportion of employed patients varied from 28 to 82%, with an extreme heterogeneity between studies. Overall, the pooled proportion of workers was 50% (95% CI 41-60%). Subgroup analyses suggested a possible, although not significant, higher proportion of workers among women, younger participants, those with a higher level of education, shorter MG duration, and less frequently thymectomized, whereas a lower proportion was observed among those with generalized, bulbar, and respiratory symptoms.

CONCLUSIONS

The results of our meta-analysis show that the percentage of employment is considerably low if we take into account that the mean age of MG patients involved in the included studies was around 48 years, thus in peak of working life. Therefore, it is important to understand what kind of influence MG exerts on work dynamics.

摘要

简介

重症肌无力(MG)是一种自身免疫性疾病,其典型发病期在 20-40 岁左右(即早发),因此正值工作年龄高峰期,或在 60-80 岁左右(即晚发)。然而,有关工作相关问题和就业状况的信息很少,且没有系统报告。因此,我们进行了系统的文献综述和荟萃分析,以解决 MG 患者的就业状况。

方法

我们检索了 2000 年 1 月至 2019 年 5 月间发表的有关 MG 患者就业状况的论文。提取有关就业的信息。使用随机效应模型生成就业患者比例的荟萃分析估计值。

结果

共检索到 1045 条记录,其中 19 条符合纳入标准。共有 3600 名参与者(平均年龄 47.5 岁,范围 35-60 岁)纳入研究,其中 1579 人就业。就业患者的比例从 28%到 82%不等,研究之间存在明显的异质性。总体而言,工人的总体比例为 50%(95%CI 41-60%)。亚组分析表明,女性、年轻参与者、教育程度较高、MG 病程较短、胸腺切除较少的患者中,工人的比例可能较高,但在全身性、延髓性和呼吸性症状患者中,工人的比例较低。

结论

我们的荟萃分析结果表明,如果考虑到纳入研究的 MG 患者的平均年龄约为 48 岁,即处于工作高峰期,那么就业的百分比相当低。因此,了解 MG 对工作动态的影响非常重要。

相似文献

1
Employment in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis.重症肌无力患者的就业状况:系统文献回顾和荟萃分析。
Neuroepidemiology. 2020;54(4):304-312. doi: 10.1159/000506310. Epub 2020 Feb 25.
2
Employment in refractory myasthenia gravis: A Myasthenia Gravis Foundation of America Registry analysis.难治性重症肌无力患者的就业状况:美国重症肌无力基金会注册分析。
Muscle Nerve. 2019 Dec;60(6):700-706. doi: 10.1002/mus.26694. Epub 2019 Oct 22.
3
Prevalence and risk factors of myasthenia gravis recurrence post-thymectomy.胸腺瘤切除术后重症肌无力复发的患病率和危险因素。
Neurosciences (Riyadh). 2021 Jan;26(1):4-14. doi: 10.17712/nsj.2021.1.20190041.
4
Clinical features and impact of myasthenia gravis disease in Australian patients.澳大利亚患者重症肌无力疾病的临床特征及影响
J Clin Neurosci. 2015 Jul;22(7):1164-9. doi: 10.1016/j.jocn.2015.01.022. Epub 2015 May 26.
5
[Late onset forms of myasthenia gravis. Comparison with early-onset myasthenia gravis].[重症肌无力的迟发型。与早发型重症肌无力的比较]
Rev Neurol (Paris). 2006 Oct;162(10):990-6. doi: 10.1016/s0035-3787(06)75109-8.
6
Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.比较新诊断全身型重症肌无力和难治性全身型重症肌无力的利妥昔单抗治疗效果。
JAMA Neurol. 2020 Aug 1;77(8):974-981. doi: 10.1001/jamaneurol.2020.0851.
7
Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.回复拉赫曼·希里博士的来信:职业群体中的自杀这一具有挑战性的话题。
Scand J Work Environ Health. 2018 Jan 1;44(1):108-110. doi: 10.5271/sjweh.3698. Epub 2017 Dec 8.
8
Myasthenia gravis (MG): epidemiological data and prognostic factors.重症肌无力(MG):流行病学数据及预后因素
Ann N Y Acad Sci. 2003 Sep;998:413-23. doi: 10.1196/annals.1254.054.
9
Study of the prevalence of familial autoimmune myasthenia gravis in a Spanish cohort.西班牙队列中家族性自身免疫性重症肌无力患病率的研究。
J Neurol Sci. 2016 Jan 15;360:110-4. doi: 10.1016/j.jns.2015.11.049. Epub 2015 Nov 27.
10
The Association Between Asthma and Risk of Myasthenia Gravis: A Systematic Review and Meta-analysis.哮喘与重症肌无力风险之间的关联:系统评价和荟萃分析。
Lung. 2021 Jun;199(3):273-280. doi: 10.1007/s00408-021-00444-8. Epub 2021 May 13.

引用本文的文献

1
Factors Influencing Quality of Life in Myasthenia Gravis Patients: Results From a Cross-Sectional Study in South of Iran.影响重症肌无力患者生活质量的因素:伊朗南部一项横断面研究的结果
Brain Behav. 2025 Aug;15(8):e70680. doi: 10.1002/brb3.70680.
2
Assessment of functioning using the WHODAS 2.0 among people with myasthenia gravis-associated disability: a nationwide follow-up study.使用世界卫生组织残疾评定量表2.0对重症肌无力相关残疾患者的功能进行评估:一项全国性随访研究。
BMC Public Health. 2025 Jul 2;25(1):2210. doi: 10.1186/s12889-025-23328-5.
3
Racial disparities in acute care utilization among individuals with myasthenia gravis.
重症肌无力患者在急性护理利用方面的种族差异。
Front Public Health. 2025 Feb 3;13:1448803. doi: 10.3389/fpubh.2025.1448803. eCollection 2025.
4
Risk of Exacerbation and Level of Healthcare Resource Utilization in Myasthenia Gravis Assessed by Myasthenia Gravis Activities of Daily Living Score.通过重症肌无力日常生活活动评分评估的重症肌无力病情加重风险及医疗资源利用水平
Neurol Ther. 2025 Apr;14(2):575-591. doi: 10.1007/s40120-025-00711-3. Epub 2025 Feb 17.
5
Epidemiology, management and patient needs in myasthenia gravis: an Italian multistakeholder consensus based on Delphi methodology.重症肌无力的流行病学、管理及患者需求:基于德尔菲法的意大利多利益相关方共识
BMJ Open. 2024 Dec 22;14(12):e086225. doi: 10.1136/bmjopen-2024-086225.
6
Myasthenia Gravis: utilising cross-platform quantitative content analysis to uncover and validate unmet needs.重症肌无力:利用跨平台定量内容分析来发现和验证未满足的需求。
Front Neurol. 2024 Sep 27;15:1474347. doi: 10.3389/fneur.2024.1474347. eCollection 2024.
7
Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population-based registry study.丹麦、芬兰和瑞典重症肌无力的经济和社会负担:基于人群的登记研究。
Eur J Neurol. 2024 Dec;31(12):e16511. doi: 10.1111/ene.16511. Epub 2024 Oct 9.
8
Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis.改善和规范全身性重症肌无力患者评估的专家共识建议。
Eur J Neurol. 2024 Jul;31(7):e16280. doi: 10.1111/ene.16280. Epub 2024 Mar 24.
9
Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy.重新聚焦广义重症肌无力:患者负担、疾病特征和不断发展的治疗方法的作用。
Eur J Neurol. 2024 Jun;31(6):e16180. doi: 10.1111/ene.16180. Epub 2023 Dec 20.
10
Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis.ravulizumab对全身型重症肌无力患者预后及生活质量的影响
Patient Relat Outcome Meas. 2023 Oct 18;14:305-312. doi: 10.2147/PROM.S408175. eCollection 2023.